Emcure Pharmaceuticals Ltd announced on Tuesday, December 23, that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (FDA) for its manufacturing facility located in Gujarat, with the inspection outcome classified as ‘No Action Indicated’ (NAI).
The FDA performed a surveillance inspection at the company’s manufacturing site in Kadu village, Surendranagar district, Gujarat, from October 6-10, 2025.
Emcure indicated that the inspection concluded without any observations, demonstrating adherence to the regulator’s Current Good Manufacturing Practice (cGMP) standards.
The NAI classification signifies that the FDA found no objectionable conditions during the inspection and does not plan to take any regulatory or enforcement measures against the facility.
Recently, the company revealed its foray into the obesity and metabolic health market with the introduction of Poviztra, a semaglutide injection aimed at chronic weight management.
In an exchange filing, Emcure stated it is the first Indian company to solely distribute and commercialize Poviztra, which is marketed as a second brand of Novo Nordisk’s semaglutide for weight management.
Also Read: Ajanta Pharma signs in-licensing pact with Biocon for marketing semaglutide in 26 countries
The medication will be available nationwide in a once-weekly pen device and will be offered in five different dosage strengths. Prices will start at ₹8,790 per month for four weekly doses, as per the company’s statement.
Shares of Emcure Pharmaceuticals Ltd closed higher on Tuesday, December 23, increasing by 3.40% to ₹1,426 on the NSE.
Also Read: OYO Parent-PRISM gains shareholder approval for ₹6,650 crore IPO
